Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis

Trial Profile

A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Betamethasone dipropionate (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Promius Pharma
  • Most Recent Events

    • 01 Jun 2016 Results published in Dr Reddys Laboratories media release.
    • 01 Jun 2016 Primary endpoint (Tretment success) has been met, as per Dr Reddys Laboratories media release.
    • 07 Feb 2016 According to a Dr. Reddy's Laboratories media release, the US FDA has approved betamethasone dipropionate (Sernivo) spray 0.05%, a prescription topical steroid, indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top